October 14th 2024
The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
September 16th 2024
Health Equity in Pharma: Communities Most Impacted by Racial Bias
July 5th 2023Rose Blackburne, MD, MBA, vice president, global head, general medicine, PPD Clinical Research, Thermo Fisher Scientific, discusses health equity in pharma, specifically racial biases, and how the industry can address inequities in access and care going forward.
A New Era for Market Access: Organizing the Function’s Broader Strategic Role
May 10th 2023BCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.
Rethinking Unmet Patient Medical Needs Through the Lens of the Patient Journey
April 7th 2023Biopharma companies can foster patient-centered innovation by focusing on unmet needs along each stage of the patient journey while collaborating with key stakeholders directly or indirectly responsible for disease management.
There’s a Need for PBMs, but also a Need for Change
March 31st 2023Rohit Gupta, vice president of analytics strategy and transformation at Beghou Consulting, addresses the controversial middlemen of the drug pricing world, the pharmacy benefit managers (PBMs). Can increased competition and other innovative solutions loosen their grip and prevent further consolidation?
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
January 11th 2023As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.
Biopharma’s Untapped Value: The Quest to Reverse First-Launch Failure Trends
December 8th 2022Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
September 9th 2022Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.